La cadena de opciones muestra datos clave de las opciones de acciones de Corbus Pharmaceuticals a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para Corbus Pharmaceuticals..

Corbus Pharmaceuticals (NASDAQ:CRBP) Bolsa, Cadena de Opciones

CORBUS PHARMACEUTICALS HOLDI

Corbus Pharmaceuticals

Corbus Pharmaceuticals Holdings Inc is a precision oncology company with a diversified portfolio and is committed to helping people defeat serious illness by bringing scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.

Corbus Pharmaceuticals Holdings, Inc. - Common Stock

Corbus Pharmaceuticals Holdings Inc

Most people don't look at their house, imagine it in flames, and think, "Eh, I'll just write a check." But Charlie Munger wasn't most people.
In one of his final public appearances—just months before his death at age 99—the longtime vice chairman of Berkshire Hathaway made a comment that raised eyebrows, especially considering the business he helped run. "Once I got rich, I stopped carrying fire insurance on houses," Munger said during the <a href="https://www.cnbc.com/2023/02/15/charlie-munger-discusses-investing-at-the-daily-journal-annual-meeting.html">2023 Daily Journal shareholder meeting</a>. "I just self-insure."
Don't Miss:
<ul class="wp-block-list">
<li>‘Scrolling To UBI' — Deloitte's #1 fastest-growing software company allows users to earn money on their phones. <a href="https://www.benzinga.com/money/mode-mobile-2">You can invest today for just $0.30/share with a $1000 minimum.</a></li>
<li>Maker of the $60,000 foldable home has 3 factory buildings, 600+ houses built, and big plans to solve housing —<a href="https://www.benzinga.com/money/boxabl"> this is your last chance to become an investor for $0.80 per share.</a></li>
</ul>
It was a surprisingly personal stance from the longtime vice chairman of Berkshire Hathaway, a conglomerate that <a href="https://www.berkshirehathaway.com/subs/sublinks.html">owns some of the biggest insurance businesses</a> in the country—Geico, General Re, Berkshire Hathaway Specialty Insurance, and more.&nbsp;
Still, Munger was unapologetic. "I'd rather tell it the way it is than tell it in a way that helps Berkshire," he said. "Even though it's bad for Berkshire, I want to tell you: if you can afford to self-insure, self-insure."
He clarified that he wasn't just talking about fire insurance. "In my own life, I'm a big self-insurer, and so is Warren," he said. "Why would you want to fool around with a claims process and all kinds of things?" His point was simple: if you're wealthy enough to absorb the loss, bypass the middlemen, avoid the red tape, and deal with problems directly.
Trending: <a href="https://www.benzinga.com/money/are-you-rich">Are you rich?</a> Here&#8217;s what Americans think you need to be considered wealthy.
That's not to say Munger was advocating recklessness. He emphasized that the decision to self-insure only makes sense if you can comfortably handle the expense. "You should insure against things you can't afford to pay for yourself," he said. "But if you can afford to take the bumps… why would you want to fool around with some insurance company?"
And it's <a href="https://www.bankrate.com/insurance/homeowners-insurance/home-insurance-required/">not an option for most people</a>. If you have a mortgage, insurance isn't just recommended—it's required by lenders. Even homeowners who own their property outright might still be subject to homeowners association regulations or local ordinances that mandate certain types of coverage. In many cases, self-insurance isn't just risky—it's off the table entirely.
Munger knew he <a href="https://www.benzinga.com/personal-finance/25/02/43700703/to-pay-28000-a-year-in-insurance-for-a-2000-square-foot-condo-is-ridiculous-suze-orman-shares-how-she-self-insures">had the resources to take on the risk</a>. "If your house burned down, I would just write a check and rebuild it," he said. And while that line might sound cavalier, it's really just an extension of how he viewed efficiency. He saw traditional insurance as a system bogged down by fraud, fees, and friction—and if you didn't need it, why get tangled in it?
See Also: <a href="https://www.benzinga.com/money/mark-cubans-advice-for-lotto-winners">Many are surprised by Mark Cuban's advice for lotto winners: Cash or annuity?</a>
So, should you self-insure? That's a personal decision, and it's a risk. Munger's approach worked for him because he could afford for something to go wrong—and because he was willing to accept the consequences if it did. But unless you're ready to pay for the full cost of disaster, both financially and emotionally, insurance might still be worth the hassle.
It's a philosophy grounded in pure Munger logic: eliminate what's wasteful, do what's rational, and ignore the noise. Just make sure, before you follow in his footsteps, that you <a href="https://www.benzinga.com/money/are-you-rich">can actually afford the walk</a>.
Read Next:
<ul class="wp-block-list">
<li>The team behind $6B+ in licensing deals is now building the next billion-dollar IP empire — <a href="https://www.benzinga.com/money/elf-labs-ym?v=123">invest early at $2.25/share.</a></li>
<li>Inspired by Uber and Airbnb &#8211; Deloitte's fastest-growing software company is transforming 7 billion smartphones into income-generating assets &#8211; <a href="https://www.benzinga.com/money/mode-mobile-2">with $1,000 you can invest at just $0.30/share!</a></li>
</ul>
Image: Shutterstock

Personal Finance

Billionaire Charlie Munger Said He Dropped Insurance After Getting Rich — 'All Intelligent People Self-Insure' If They Can Afford It

MLEC

Trading Halt: Halted at 7:50:00 p.m. ET - Trading Halt: Halt News Pending

MLECW

Longevity Health Holdings, Inc. - Common Stock

XAGE

XAGEW

Palo Alto Networks (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PANW#NASDAQ">PANW</a>) has outperformed the market over the past 10 years by 11.29% on an annualized basis producing an average annual return of 21.95%. Currently, Palo Alto Networks has a market capitalization of $127.13 billion. 
Buying $1000 In PANW: If an investor had bought $1000 of PANW stock 10 years ago, it would be worth $7,303.62 today based on a price of $192.01 for PANW at the time of writing.
<h3>Palo Alto Networks's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1747179917_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

News

Trading Ideas

PANW

$1000 Invested In This Stock 10 Years Ago Would Be Worth This Much Today

Carvana (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVNA#NYSE">CVNA</a>) has outperformed the market over the past 5 years by 9.6% on an annualized basis producing an average annual return of 24.34%. Currently, Carvana has a market capitalization of $39.27 billion. 
Buying $1000 In CVNA: If an investor had bought $1000 of CVNA stock 5 years ago, it would be worth $3,162.75 today based on a price of $292.33 for CVNA at the time of writing.
<h3>Carvana's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1747179011_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CVNA

If You Invested $1000 In This Stock 5 Years Ago, You Would Have This Much Today

HealthEquity (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HQY#NASDAQ">HQY</a>) has outperformed the market over the past 10 years by 3.4% on an annualized basis producing an average annual return of 14.06%. Currently, HealthEquity has a market capitalization of $8.39 billion. 
Buying $1000 In HQY: If an investor had bought $1000 of HQY stock 10 years ago, it would be worth $3,740.46 today based on a price of $96.99 for HQY at the time of writing.
<h3>HealthEquity's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1747178115_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much You Would Have Made Owning HealthEquity Stock In The Last 10 Years

Billionaire investor Mark Cuban took another shot at Commerce Secretary Howard Lutnick in his latest post. Over the weekend, Cuban took to <a href="https://bsky.app/profile/mcuban.bsky.social/post/3lovvp2fzcc2j">Bluesky</a> to mock Lutnick, writing, "I wonder which Time Share company Howard Lutnick is going to get a job in sales at."
<h2 class="wp-block-heading">Lutnick&#8217;s Controversial Tenure</h2>
Cuban&#8217;s jab comes on the heels of a series of critical comments he&#8217;s made about Lutnick's tenure as commerce secretary. In March, for instance, Cuban questioned Lutnick&#8217;s effectiveness, <a href="https://bsky.app/profile/mcuban.bsky.social/post/3lkxkj5mhnc2o">asking</a>, "Has Howard Lutnick done anything of value as Commerce Secretary?" The remark was a response to Lutnick&#8217;s recent controversial interviews and public comments.
Don't Miss:
<ul class="wp-block-list">
<li>‘Scrolling To UBI' — Deloitte's #1 fastest-growing software company allows users to earn money on their phones. <a href="https://www.benzinga.com/money/mode-mobile-2">You can invest today for just $0.30/share with a $1000 minimum.</a></li>
<li>Maker of the $60,000 foldable home has 3 factory buildings, 600+ houses built, and big plans to solve housing —<a href="https://www.benzinga.com/money/boxabl"> this is your last chance to become an investor for $0.80 per share.</a></li>
</ul>
One of the key points of contention is Lutnick&#8217;s approach to tariffs and trade. In a March <a href="https://bsky.app/profile/atrupar.com/post/3ljpthdit7k24">CNBC</a> interview, Lutnick defended the Trump administration's tariff strategy, emphasizing its potential to boost U.S. manufacturing. Cuban shot back on <a href="https://bsky.app/profile/did:plc:y5xyloyy7s4a2bwfeimj7r3b/post/3ljqszshvvc2k">Bluesky</a>, saying, "Someone needs to explain to our Sec of Commerce how capitalism works." He added, "America has a global trade surplus on services. Services have the highest margins and profits of our exports. That is where capital and expertise are focused."
Cuban's critiques highlight a fundamental disagreement over the direction of U.S. trade policy. Lutnick has been a vocal supporter of President Donald Trump&#8217;s tariffs, arguing that they are necessary to address the $1.2 trillion U.S. trade deficit. He defended this approach in a Sunday <a href="https://www.youtube.com/watch?v=1lx5YKNttzU">CNN</a> interview, describing the deficit as unsustainable and claiming that tariffs will help create balanced trade. "The president wants balanced and fair trade, and tariffs are the tool to create balanced and fair trade," Lutnick said.
Trending: The team behind $6B+ in licensing deals is now building the next billion-dollar IP empire — <a href="https://www.benzinga.com/money/elf-labs-ym?v=123">invest early at $2.25/share.</a>
Cuban has consistently resisted this, arguing that the U.S. should concentrate more on its robust services industry, which he claims is more lucrative and a better long-term investment for economic expansion. He also criticized Lutnick&#8217;s recent comments about Social Security, where Lutnick suggested that people who complain about missed checks might be fraudsters, sparking significant backlash.
"My mother-in-law, who&#8217;s 94, she wouldn&#8217;t call and complain. She just wouldn&#8217;t," Lutnick said on the "<a href="https://www.youtube.com/watch?v=182ckTL2KBA">All-In Podcast</a>" in March. "A fraudster always makes the loudest noise, screaming, yelling and complaining."
The latest trade developments also add context to Cuban&#8217;s criticism. This week, the U.S. and China agreed to a <a href="https://www.benzinga.com/government/regulations/25/05/45342343/us-stock-futures-rise-as-us-china-agree-to-90-day-tariff-pause-wider-earnings-growth-should-drive-more-balanced-market-performance-says-expert">90-day tariff reduction pause</a>, with the U.S. lowering tariffs on Chinese goods from 145% to 30% and China cutting duties on U.S. products from 125% to 10%. The deal, which allows for ongoing economic discussions, underscores the ongoing challenges in balancing U.S. trade interests.
Cuban&#8217;s pointed comments suggest he remains skeptical of Lutnick's approach, framing it as disconnected from the <a href="https://www.benzinga.com/25/04/44756759/new-research-shows-donald-trumps-25-tariffs-could-cost-auto-companies-108billion-report">economic realities</a> faced by <a href="https://www.benzinga.com/news/25/03/44347512/wait-tariffs-are-just-a-tax-on-us-employee-shocked-as-small-business-owner-cuts-his-hours-because-of-the-tariffs">most Americans</a>. His critiques echo broader concerns about the <a href="https://www.benzinga.com/25/05/45254241/recession-could-originate-at-the-port-of-los-angeles-warns-economist-calling-tariff-decision-a-misapplied-consumption-tax-on-households">potential economic fallout</a> from ongoing trade disputes and the effectiveness of <a href="https://www.benzinga.com/personal-finance/25/05/45338243/stephen-miller-says-history-will-record-trumps-tariffs-as-the-start-of-saving-the-west-from-chinas-economic-domination">tariffs as a long-term strategy</a>.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/money/this-ai-imaging-technology-has-been-used-in-more-than-500-surgeries-now-you-can-be-part-of-the-ai-imaging-revolution">Be part of the next med-tech breakthrough for only $350 — 500+ surgeries already done with nView's AI system.</a></li>
<li><a href="https://www.benzinga.com/money/a-cure-for-osteoarthritis-powered-by-everyday-investors-cytonics-is-looking-to-beat-big-pharma-and-disrupt-a-390-billion-market">Invest Where It Hurts — And Help Millions Heal: Invest in Cytonics and help disrupt a $390B Big Pharma stronghold.</a></li>
</ul>
Image: Shutterstock

Mark Cuban Takes A Jab At Howard Lutnick, 'In Which Time Share Company Is He Going To Get A Job In Sales At'

Microsoft (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>) has outperformed the market over the past 5 years by 4.68% on an annualized basis producing an average annual return of 19.42%. Currently, Microsoft has a market capitalization of $3.33 trillion. 
Buying $1000 In MSFT: If an investor had bought $1000 of MSFT stock 5 years ago, it would be worth $2,452.17 today based on a price of $448.40 for MSFT at the time of writing.
<h3>Microsoft's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1747177210_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

MSFT

$1000 Invested In Microsoft 5 Years Ago Would Be Worth This Much Today

Chipotle Mexican Grill (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CMG#NYSE">CMG</a>) has outperformed the market over the past 15 years by 9.66% on an annualized basis producing an average annual return of 21.35%. Currently, Chipotle Mexican Grill has a market capitalization of $68.30 billion. 
Buying $100 In CMG: If an investor had bought $100 of CMG stock 15 years ago, it would be worth $1,813.33 today based on a price of $50.69 for CMG at the time of writing.
<h3>Chipotle Mexican Grill's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1747176317_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much You Would Have Made Owning Chipotle Mexican Grill Stock In The Last 15 Years

Wall Street extended its rally on Tuesday as easing trade tensions between the U.S. and China and softer inflation data boosted investor confidence. In fact, the S&amp;P 500 reclaimed positive territory for 2025 and closed 0.7%<a href="https://www.benzinga.com/economics/macro-economic-events/25/05/45379707/sp-500-to-6500-goldman-sachs-trims-recession-odds-as-trump-backs-off-on-tariffs"> higher on the day.</a>&nbsp;
What To Know: The market is flashing another bullish signal that could indicate even more gains ahead, according to Ryan Detrick, chief market strategist for the Carson Group.&nbsp;
Detrick observed that on Tuesday, more than 60% of the components in the S&amp;P 500 are hitting new 20-day highs and pointed to a historically bullish year following this rare occurrence. 
Read Next: <a href="https://www.benzinga.com/25/05/45378427/trump-wants-to-kickstart-nuclear-development-these-5-stocks-could-boom?utm_source=articleShare">Trump Wants To Kickstart Nuclear Development: These 5 Stocks Could Boom</a>
"This is quite rare and rather bullish. Strong performance across the board and higher a year later 18 out of 18 times," Detrick wrote<a href="https://x.com/RyanDetrick/status/1922361671332303080"> in a post</a> on X.&nbsp;
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">After today we will have more than 60% of the components in the S&amp;P 500 hitting a new 20-day high. This is quite rare and rather bullish. Strong performance across the board and higher a year later 18 out of 18 times. &#x1f4aa; <a href="https://t.co/0D4Pm0scqS">pic.twitter.com/0D4Pm0scqS</a>
&mdash; Ryan Detrick, CMT (@RyanDetrick) <a href="https://twitter.com/RyanDetrick/status/1922361671332303080?ref_src=twsrc%5Etfw">May 13, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Detrick posted a chart from Carson Investment Research, which shows the last time more than 60% of S&amp;P 500 components reached a new 20-day high was on Dec. 1, 2023. Twelve months later, the S&amp;P 500 was 31.7% higher. 
The same chart indicates that this signal has flashed 18 times since 1982, and each time the S&amp;P 500 was higher 12 months later with an average gain of 18.6%.&nbsp;
What Drove The Action: First Solar Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FSLR#NASDAQ">FSLR</a>) soared almost 23% and was the biggest gainer in the S&amp;P 500 on Tuesday, on favorable U.S.<a href="https://www.benzinga.com/top-stories/25/05/45381191/first-solar-eyes-best-2-day-rally-since-2013-after-gop-tax-plan-spares-key-clean-energy-credits"> policy developments</a> for domestic solar manufacturers. 
NVIDIA Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) was a standout performer Tuesday, surging nearly 6% after announcing it <a href="https://www.benzinga.com/trading-ideas/movers/25/05/45384348/whats-going-on-with-nvidia-stock-tuesday-2">would supply </a>18,000 advanced AI chips to Saudi Arabia. The move pushed Nvidia&#8217;s market capitalization above $3 trillion and made it a major force behind the S&amp;P 500&#8217;s advance. 
Shares of Palantir Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NASDAQ">PLTR</a>) rose more than 8% to an all-time high of $130.60, <a href="https://www.benzinga.com/news/25/05/45383727/palantir-stock-hits-new-all-time-high-on-strong-earnings-macro-tailwinds">buoyed by optimism</a> around its AI software and increased defense sector opportunities. 
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/25/05/45354683/tesla-probably-wont-make-money-on-ride-hailing-for-years-gary-black-says?utm_source=articleShare">Tesla Robotaxi Hopes Dashed By Uber, Lyft: No Fast Lane To Profits, Warns Investor Gary Black&nbsp;</a></li>
</ul>
Image: Shutterstock

Analyst Color

Equities

Broad U.S. Equity ETFs

Markets

ETFs

FSLR

NVDA

PLTR

S&P 500 Turns Positive On The Year, Flashes 'Quite Rare And Rather Bullish' Signal

TherapeuticsMD (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TXMD#NASDAQ">TXMD</a>) reported quarterly losses of $(0.06) per share. This is a 14.29 percent increase over losses of $(0.07) per share from the same period last year. The company reported $393.00 thousand in sales this quarter. This is a 25.56 percent increase over sales of $313.00 thousand the same period last year.

Earnings

TXMD

TherapeuticsMD Q1 EPS $(0.06) Up From $(0.07) YoY, Sales $393.00K Up From $313.00K YoY

Sen. Bernie Sanders (I-VT) says American workers are frustrated and they have a good reason to be.&nbsp;
In a recent <a href="https://x.com/BernieSanders/status/1919106487508414676">post on X</a>, Sanders pointed out that despite decades of rising worker productivity, inflation-adjusted wages are lower today than they were 52 years ago. At the same time, he noted a massive transfer of wealth from the bottom 90% to the top 1%, calling the situation unacceptable. "The status quo is NOT working. We need real change," he wrote.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">American workers are angry. Despite increased worker productivity, inflation-adjusted wages are lower today than they were 52 years ago. At the same time, there was a huge transfer of wealth from the bottom 90% to the top 1%. The status quo is NOT working. We need real change.
&mdash; Bernie Sanders (@BernieSanders) <a href="https://twitter.com/BernieSanders/status/1919106487508414676?ref_src=twsrc%5Etfw">May 4, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Don't Miss:
<ul class="wp-block-list">
<li>Deloitte's fastest-growing software company partners with Amazon, Walmart &amp; Target – <a href="https://www.benzinga.com/money/mode-mobile-2">Many are rushing to grab 4,000 of its pre-IPO shares for just $0.30/share!</a></li>
<li>Maker of the $60,000 foldable home has 3 factory buildings, 600+ houses built, and big plans to solve housing —<a href="https://www.benzinga.com/money/boxabl"> this is your last chance to become an investor for $0.80 per share.</a></li>
</ul>
<h2 class="wp-block-heading">A Growing Gap Between Productivity and Pay</h2>
The Economic Policy Institute backs up Sanders&#8217; claims. According to a recent EPI <a href="https://www.epi.org/productivity-pay-gap/">report</a>, U.S. productivity has surged by 86.5% from 1979 to 2024, while hourly pay for typical workers only grew by 31.7% over the same period. That means productivity has grown nearly three times faster than wages, creating a wide gap between the value workers produce and what they take home.
The EPI argues this gap is not an accident but a result of policy decisions that reduced worker bargaining power, <a href="https://www.benzinga.com/news/25/01/42918620/unions-should-brace-for-competition-what-trumps-labor-revolution-means-for-workers">weakened unions</a>, and shifted more wealth to capital owners. The report points out that this shift has resulted in slower economic growth overall, with typical workers missing out on the benefits of rising productivity.
"The growing wedge between productivity and typical workers' pay is income going everywhere but the paychecks of the bottom 80% of workers," the EPI said. "If it didn't end up in paychecks of typical workers, where did all the income growth implied by the rising productivity line go? Two places, basically. It went into the salaries of highly paid corporate and professional employees. And it went into higher profits (returns to shareholders and other wealth owners)."
Trending: Nancy Pelosi Invested $5 Million In An AI Company Last Year — <a href="https://www.benzinga.com/money/elf-labs-ym?v=123">Here's How You Can Invest In Multiple Pre-IPO AI Startups With Just $1,000.</a>
<h2 class="wp-block-heading">Longer Hours, Shorter Lives</h2>
Sanders has also recently <a href="https://www.benzinga.com/news/25/03/44302734/bernie-sanders-says-stress-kills-as-he-highlights-a-7-year-life-expectancy-gap-between-the-working-class-and-the-wealthy">raised concerns about the health impact</a> of economic stress. In a recent <a href="https://www.sanders.senate.gov/wp-content/uploads/3.7.2025-Life-Expectancy-Working-Class-Report_final.pdf">report</a> from the Senate Committee on Health, Education, Labor and Pensions, he highlighted a growing life expectancy gap between the wealthy and the working class. The report found that Americans in the wealthiest 1% of counties live an average of 84.3 years, while those in the bottom 50% of counties live only 77.4 years.
One stark example from the report shows that Loudoun County, Virginia, one of the wealthiest counties in the U.S., has a life expectancy of 84 years, while McDowell County, West Virginia, one of the poorest, has a life expectancy of just 69 years—a 15-year difference despite being only about 350 miles apart.
"Stress kills," Sanders said, adding that these disparities are unacceptable in a wealthy country like the U.S. "The massive <a href="https://www.benzinga.com/personal-finance/25/01/43351521/2025-is-the-year-the-wealth-disparity-gets-much-worse-viral-finance-influencer-explains-the-trump-economic-effect">income and wealth inequality</a> that exists in America today is not just an economic issue, it is literally a matter of life and death."
See Also: Shark Tank's Kevin O'Leary called Missing Ring his biggest mistake — Don't repeat history—<a href="https://www.benzinga.com/money/big-tech-has-spent-billions-acquiring-ai-smart-home-startups-one-company-stands-to-benefit-and-has-already-made-10-million">invest in RYSE at just $1.90/share.</a>
<h2 class="wp-block-heading">Closing the Gap</h2>
To address these issues, Sanders has proposed a series of policy changes aimed at boosting workers&#8217; pay and improving their quality of life. These include <a href="https://in.benzinga.com/news/25/04/45028145/joe-rogan-agrees-with-bernie-sanders-saying-hes-right-that-you-should-be-scared-of-oligarchs-they-shouldnt-be-running-the-government">raising the minimum wage to at least $17 an hour</a>, implementing Medicare for All, expanding Social Security, providing paid family leave, and making education more affordable.
Sanders argues that these steps are essential if the U.S. is to close the growing gap between the rich and the working class and ensure that all Americans can share in the nation&#8217;s prosperity.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/money/a-cure-for-osteoarthritis-powered-by-everyday-investors-cytonics-is-looking-to-beat-big-pharma-and-disrupt-a-390-billion-market">Invest Where It Hurts — And Help Millions Heal: Invest in Cytonics and help disrupt a $390B Big Pharma stronghold.</a></li>
<li>‘Scrolling To UBI' — Deloitte's #1 fastest-growing software company allows users to earn money on their phones. <a href="https://www.benzinga.com/money/mode-mobile-2">You can invest today for just $0.30/share with a $1000 minimum.</a></li>
</ul>
Image: Shutterstock

Bernie Sanders Says 'American Workers Are Angry' Because Wages Haven't Kept Up—'They Are Lower Today Than They Were 52 Years Ago'

UMB Financial (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UMBF#NASDAQ">UMBF</a>) has outperformed the market over the past 5 years by 3.2% on an annualized basis producing an average annual return of 17.95%. Currently, UMB Financial has a market capitalization of $8.20 billion. 
Buying $1000 In UMBF: If an investor had bought $1000 of UMBF stock 5 years ago, it would be worth $2,487.10 today based on a price of $107.99 for UMBF at the time of writing.
<h3>UMB Financial's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1747175410_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

UMBF

$1000 Invested In UMB Financial 5 Years Ago Would Be Worth This Much Today

Flora Growth (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FLGC#NASDAQ">FLGC</a>) reported quarterly losses of $(0.04) per share which beat the analyst consensus estimate of $(0.16) by 75 percent. This is a 89.47 percent increase over losses of $(0.38) per share from the same period last year. The company reported quarterly sales of $11.79 million which missed the analyst consensus estimate of $15.42 million by 23.55 percent. This is a 34.63 percent decrease over sales of $18.03 million the same period last year.

Earnings Beats

Earnings Misses

FLGC

Flora Growth Q1 EPS $(0.04) Beats $(0.16) Estimate, Sales $11.79M Miss $15.42M Estimate

Anebulo Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANEB#NASDAQ">ANEB</a>) reported quarterly losses of $(0.04) per share which beat the analyst consensus estimate of $(0.05) by 20 percent. This is a 33.33 percent increase over losses of $(0.06) per share from the same period last year.

ANEB

Anebulo Pharmaceuticals Q3 EPS $(0.04) Beats $(0.05) Estimate

Lightwave Logic (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LWLG#NASDAQ">LWLG</a>) reported quarterly losses of $(0.04) per share. This is a 20 percent increase over losses of $(0.05) per share from the same period last year. The company reported $22.92 thousand in sales this quarter. This is a 24.66 percent decrease over sales of $30.42 thousand the same period last year.

LWLG

Lightwave Logic Q1 EPS $(0.04) Up From $(0.05) YoY, Net Sales $22.92K Down From $30.42K YoY

Ambase (OTC:<a class="ticker" href="https://www.benzinga.com/stock/ABCP#OTC">ABCP</a>) reported quarterly losses of $(0.02) per share. This is a 60 percent increase over losses of $(0.05) per share from the same period last year.

ABCP

Ambase Q1 EPS $(0.02) Up From $(0.05) YoY

Satellogic (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SATL#NASDAQ">SATL</a>) reported quarterly losses of $(0.34) per share. This is a 100 percent decrease over losses of $(0.17) per share from the same period last year. The company reported $3.39 million in sales this quarter. This is a 1.77 percent increase over sales of $3.33 million the same period last year.

SATL

CORRECTION: Satellogic Q1 EPS $(0.34) Down From $(0.17) YoY, Sales $3.39M Up From $3.33M YoY

Press Releases

Corbus Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Health Care

Corbus Pharmaceuticals Announces that Clinical Data for CRB-701 from Western Dose Escalation Study to be Presented at ASCO GU 2025

Corbus Pharmaceuticals to Present at the Guggenheim SMID Cap Biotech Conference

Corbus Pharmaceuticals Announces Clinical Data for CRB-701 from Western Dose Escalation Study to be Presented at 2025 ASCO-GU

CRB-701 (SYS6002) A Next Generation Nectin-4 Targeting ADC Demonstrates Encouraging Safety and Broader Efficacy in Phase 1 Study in the US and UK Presented at ASCO-GU 2025

Corbus Pharmaceuticals to Participate in Upcoming Investor Conferences

Corbus Pharmaceuticals Reports Q4 and 2024 Financial Results and Provides a Corporate Update

General

Corbus Pharmaceuticals Announces First Patient Dosed in Phase 1 Clinical Study of Next-Generation CB1 Inverse Agonist CRB-913 for the Treatment of Obesity

Comments

Corbus Pharmaceuticals

Corbus Pharmaceuticals (CRBP) Opciones

Corbus Pharmaceuticals (NASDAQ:CRBP) Bolsa, Cadena de Opciones

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL